UNSPSC 51411604: Dilevalol

This classification denotes a vasodilating agent and adrenergic antagonist with the molecular formula C19H24N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier P6629XE33T, chemically known as (r,r)-labetalol but generally known as dilevalol, which bears US NIH Compound Identifier 134044. European Medicines Agency schedules Dilevalol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07145MIG. The term DILEVALOL is an International Non-Proprietary Name.

UNSPSC 51411604 Dilevalol, a Commodity code, encompasses pharmaceutical products that state and local governments procure for emergency medical services, public health programs, and multistate cooperative purchasing initiatives. The recent solicitation activity shows state and local buyers acquiring both branded and generic medications—including advanced life support drugs like epinephrine, adenosine, diltiazem, and labetalol—through sealed competitive bids, cooperative purchasing RFPs, and exploratory RFIs designed to reshape pharmacy benefit procurement. Issuing bodies include municipal fire and rescue departments, state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across multiple jurisdictions. The scope of work spans direct supply of medications with strict expiration-date and delivery requirements, direct-to-manufacturer pharmacy programs seeking to bypass traditional pharmacy benefit managers and wholesalers, and standing-order agreements with authorized wholesale distributors that require manufacturers to maintain cGMP certification, DSCSA compliance, and specific pricing and EDI capabilities.

Recent activity concentrates in Texas, Florida, and Minnesota. The City of Tampa's Purchasing Department issued IFB 26P00188 on April 24, 2026, for advanced life support medications to support Tampa Fire Rescue, with a response due April 8, 2026, and an estimated contract value of $40,000, incorporating a 5 percent SLBE bid discount. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), released an RFP for generic multi-source pharmaceuticals and OTC products on January 20, 2026, due March 26, 2026, requiring vendors to work through three authorized wholesalers and certify cGMP and DSCSA compliance, with contract terms of two years effective July 1, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to explore vendor capabilities for direct-to-manufacturer prescription programs outside traditional PBM and GPO arrangements. All three solicitations require detailed product information, compliance documentation, and insurance coverage; the cooperative purchasing track emphasizes price competitiveness and administrative fee transparency, while emergency-services procurement prioritizes rapid fulfillment and supply-chain continuity.